Department of Clinical Neurophysiology, Danish Centre for Sleep Medicine, University of Copenhagen, Glostrup Hospital, Denmark.
Acta Neurol Scand. 2010 Apr;121(4):265-70. doi: 10.1111/j.1600-0404.2009.01227.x. Epub 2009 Dec 28.
In the absence of socio-economical consequences of hypersomnia this study addresses the factual indirect and direct costs.
Two thousand two hundred and eight patients with a hypersomnia diagnosis from 1998 to 2005 were identified in the Danish national patient registry (NPR), each compared with 4 age and gender adjusted, randomly chosen citizens selected from the Civil Registration System Statistics. The health cost was decomposed in direct and indirect yearly costs, including labor supply and social transfer payments. Direct costs included frequencies and costs of discharges and outpatient use by cost weights according to diagnosis related groups and specific outpatient prices based on data from The Danish Ministry of Health. The use of and costs of drugs was based on data from the Danish Medicines Agency. The frequencies and costs from primary sectors were based on data from The National Health Security. Indirect costs were based on income data from the coherent social statistics (CSS).
Patients with hypersomnia presented significant higher health related contact rate, expenses and medication use. No differences were identified in employment and income. The yearly sum of direct and indirect costs were yearly euro3402 vs. euro1212 in controls (P < 0.001), corresponding to a yearly excess costs euro2190. The patients presented higher transfer income, total euro889.
Hypersomnia patient present higher health and medication uses, and social transfer income and thus represent a significant socio-economical burden.
本研究旨在探讨嗜睡症的实际间接和直接成本，而不考虑其社会经济后果。
从丹麦全国患者登记处（NPR）中确定了 1998 年至 2005 年间的 2208 例嗜睡症患者，每位患者与从民事登记系统统计中随机选择的 4 名年龄和性别相匹配的公民进行对照。将健康成本分解为直接和间接年度成本，包括劳动力供应和社会转移支付。直接成本包括根据诊断相关组和特定门诊价格按成本权重计算的出院和门诊使用频率和成本，这些价格基于丹麦卫生部的数据。药物使用和成本基于丹麦药品管理局的数据。初级部门的使用频率和成本基于国家卫生保障的数据。间接成本基于连贯社会统计数据（CSS）中的收入数据。
嗜睡症患者的健康相关接触率、费用和用药量明显更高。但在就业和收入方面未发现差异。直接和间接成本的年总和分别为患者组的 3402 欧元和对照组的 1212 欧元（P < 0.001），每年超额成本为 2190 欧元。患者的转移收入较高，总额为 889 欧元。
嗜睡症患者的健康和药物使用量更高，社会转移收入更高，因此代表了重大的社会经济负担。
